Loading
A phase 2 trial of vudalimab in ovarian cancer, endometrial cancer, cervical cancer and prostate cancer, run by Xencor, Inc., active and no longer recruiting.
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies is a phase 2 interventional study registered as NCT05032040 by Xencor, Inc., with 170 participants enrolled, started 2022-07-21 and due to reach its primary completion in 2025-10-15. Interventions recorded: vudalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ICON plc and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares ICON plc and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/